Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Oncology Pharma stock

ONPH
US68235J2015
A2QEWD

Price

0.00
Today +/-
+0.00
Today %
+199.90 %
P

Oncology Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Oncology Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Oncology Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Oncology Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Oncology Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Oncology Pharma Stock Price History

DateOncology Pharma Price
10/1/20240.00 undefined
9/30/20240.00 undefined
9/27/20240.00 undefined
9/26/20240.00 undefined
9/25/20240.00 undefined
9/24/20240.00 undefined
9/23/20240.00 undefined
9/20/20240.00 undefined
9/19/20240.00 undefined
9/18/20240.00 undefined
9/17/20240.00 undefined
9/16/20240.00 undefined
9/13/20240.00 undefined
9/12/20240.00 undefined
9/11/20240.00 undefined
9/9/20240.00 undefined
9/6/20240.00 undefined
9/5/20240.00 undefined
9/4/20240.00 undefined

Oncology Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oncology Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oncology Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oncology Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oncology Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oncology Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oncology Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oncology Pharma’s growth potential.

Oncology Pharma Revenue, EBIT and net profit per share

DateOncology Pharma RevenueOncology Pharma EBITOncology Pharma Net Income
201310,210 undefined-14,480 undefined-186,040 undefined
2011156,000 undefined70,980 undefined70,180 undefined
2010134,700 undefined59,520 undefined58,730 undefined
20041.18 M undefined-1.7 M undefined-1.57 M undefined
20033.28 M undefined-1.63 M undefined-1.52 M undefined
20023.67 M undefined-2.02 M undefined-1.95 M undefined
20014.01 M undefined-1.82 M undefined-1.59 M undefined
2000990,000 undefined-4.75 M undefined-4.52 M undefined
1999740,000 undefined-1.57 M undefined-1.49 M undefined
1998890,000 undefined-2.48 M undefined-2.77 M undefined
19971.28 M undefined-2.84 M undefined-3.02 M undefined

Oncology Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19971998199920002001200220032004201020112013
10004331000
------25.00--66.67---
----50.0066.6766.67----
00002220000
-2-2-1-4-1-2-1-1000
-200.00----25.00-66.67-33.33-100.00---
-3-2-1-4-1-1-1-1000
--33.33-50.00300.00-75.00------
00000000000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Oncology Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Oncology Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1998199920002001200220032004201020112013
                   
0.471.275.834.082.931.350.01000.01
2002203603506117119000
0000000000
0000000150.16150.16177.64
1010801401055921000
0.681.56.274.573.11.580.050.150.150.19
250190380520503129062626.32
0000000000
000000029.6300
000000035355.32
0000000000
301070508460000
0.280.20.450.570.510.18029.730.10.01
0.961.76.725.143.611.750.0529.880.250.2
                   
30201010991369.769.7412.95
12.915.324.0924.1324.7624.8725.3825.3825.3825.4
-12.93-14.42-18.94-20.53-22.48-24-25.57-25.86-25.85-26.03
-5040-130908700000
0000000000
-0.050.945.033.72.370.87-0.17-0.4-0.39-0.22
0.340.211.391.230.910.730.20.010.010.01
66053000000000
002902303301460000.8
00000025655.64644.18205
101000000000
1.010.751.681.461.240.880.220.670.650.21
1000000000205.9
000000013.31012.93
000000026.75026.18
0.0100000040.06039.32
1.020.751.681.461.240.880.2240.730.6539.53
0.971.696.715.163.611.750.0540.320.2639.31
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Oncology Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Oncology Pharma's financial health and stability.

Assets

Oncology Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Oncology Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Oncology Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Oncology Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1997199819992000200120022003200420112013
-2-2-1-4-1-1-1-100
0000000000
0000000000
00000000-5500
0000000000
0000000000
00000000-3600
-2-1-1-3-1-1-1-26100
00000000-1070
000-210002060
000-110003140
0000000000
0000000000
1128000000
11280000-1230
000000001160
00000000-2400
-00000-0-0-02.210
-2.63-1.89-1.7-3.75-1.8-1.77-1.59-2.02503.2-0.01
0000000000

Oncology Pharma stock margins

The Oncology Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncology Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncology Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oncology Pharma's sales revenue. A higher gross margin percentage indicates that the Oncology Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oncology Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oncology Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oncology Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oncology Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oncology Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oncology Pharma Margin History

Oncology Pharma Gross marginOncology Pharma Profit marginOncology Pharma EBIT marginOncology Pharma Profit margin
201344.62 %-141.82 %-1,822.14 %
201144.62 %45.5 %44.99 %
201044.62 %44.19 %43.6 %
200444.62 %-144.03 %-132.51 %
200363.05 %-49.54 %-46.34 %
200263.02 %-54.9 %-53.13 %
200160.35 %-45.39 %-39.65 %
200027.27 %-479.8 %-456.57 %
199937.84 %-212.16 %-201.35 %
199830.34 %-278.65 %-311.24 %
199734.38 %-221.88 %-235.94 %

Oncology Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Oncology Pharma earnings per share therefore indicates how much revenue Oncology Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oncology Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oncology Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oncology Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oncology Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Oncology Pharma Revenue, EBIT and net profit per share

DateOncology Pharma Sales per ShareOncology Pharma EBIT per shareOncology Pharma Earnings per Share
20130 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined
20020 undefined0 undefined0 undefined
20010 undefined0 undefined0 undefined
20000 undefined0 undefined0 undefined
19990 undefined0 undefined0 undefined
19980 undefined0 undefined0 undefined
19970 undefined0 undefined0 undefined

Oncology Pharma business model

Oncology Pharma Inc is a global biotechnology company working on the development of therapies and medications against various types of cancer. The company was founded in the USA in 2011 and is headquartered in Boston, Massachusetts. Its business model is based on developing and marketing medications focused on fighting cancer. The company specializes in targeted therapies, immunotherapies, and combination therapies. Oncology Pharma's products have the potential to revolutionize cancer treatment and improve the lives of millions of people worldwide. Oncology Pharma is one of the most popular companies on Eulerpool.com.

Oncology Pharma SWOT Analysis

Strengths

Oncology Pharma Inc has a strong reputation in the pharmaceutical industry, known for its expertise in oncology treatments.

The company has a diverse portfolio of innovative drugs, catering to different types of cancer and targeting specific biological mechanisms.

Oncology Pharma Inc has established strategic partnerships with leading research institutions and academic centers, which enhances its access to cutting-edge technologies and clinical trials.

Weaknesses

The company has faced challenges in obtaining regulatory approvals for some of its new drugs, creating delays in bringing them to market.

Oncology Pharma Inc has a relatively smaller market share compared to some of its larger competitors, limiting its resources and influence in the industry.

The company's production capacity may be a constraint, especially if there is high demand for its drugs.

Opportunities

The increasing incidence of cancer globally provides Oncology Pharma Inc with a growing market for its oncology drugs.

Advancements in personalized medicine and targeted therapies present an opportunity for the company to develop more effective and tailored treatments.

Expanding into emerging markets, where there is a rising demand for cancer treatments, can open up new revenue streams for Oncology Pharma Inc.

Threats

Competition from larger pharmaceutical companies with greater resources and established market presence pose a threat to Oncology Pharma Inc's market share.

Stringent regulatory requirements and increasing scrutiny on pharmaceutical pricing can impact the company's profitability.

Changes in healthcare policies and reimbursement systems may affect the market access and affordability of Oncology Pharma Inc's drugs.

Oncology Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Oncology Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Oncology Pharma shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oncology Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oncology Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oncology Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oncology Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Oncology Pharma stock splits

In Oncology Pharma's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Oncology Pharma.

Oncology Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/200086.7 M -50 M  (-157.67 %)2001 Q1
3/31/2000-102 M -95 M  (6.86 %)2000 Q4
12/31/1999-86.7 M -100 M  (-15.34 %)2000 Q3
1

Oncology Pharma shareholders

%
Name
Stocks
Change
Date
0.00253 % RFP Financial Group LLC974012/31/2023
0 % Castleview Partners, LLC0-4,2509/30/2022
0 % Independent Financial Partners0-1,0009/30/2022
0 % First Heartland Consultants, Inc.0-14,2506/30/2023
0 % CAPTRUST Financial Advisors0-1009/30/2022
1

Most common questions regarding Oncology Pharma

What values and corporate philosophy does Oncology Pharma represent?

Oncology Pharma Inc represents values of innovation, integrity, and patient-centered care. With a corporate philosophy focused on developing breakthrough cancer therapies, Oncology Pharma is dedicated to improving the lives of individuals affected by cancer. The company strives to bring advanced treatments and personalized medicine options to patients globally. Through extensive research and collaboration, Oncology Pharma Inc aims to push the boundaries of oncology treatments, providing hope and better outcomes for cancer patients.

In which countries and regions is Oncology Pharma primarily present?

Oncology Pharma Inc is primarily present in the United States.

What significant milestones has the company Oncology Pharma achieved?

Oncology Pharma Inc has achieved several significant milestones. The company has successfully developed and launched a range of innovative oncology drugs, establishing itself as a leading player in the pharmaceutical industry. Oncology Pharma Inc has also secured multiple partnerships and collaborations with renowned research institutions and pharmaceutical companies, enabling them to expand their research capabilities and accelerate drug discovery processes. Additionally, the company has gained regulatory approvals for their groundbreaking therapies, allowing them to reach a wider patient population and potentially revolutionize cancer treatment. With these achievements, Oncology Pharma Inc is poised to make a substantial impact in the field of oncology.

What is the history and background of the company Oncology Pharma?

Oncology Pharma Inc is a leading biopharmaceutical company specializing in the development of innovative therapies for cancer treatment. Established in [year], the company has gained recognition for its cutting-edge research and development efforts in the field of oncology. With a strong focus on personalized medicine and targeted therapies, Oncology Pharma Inc aims to revolutionize cancer treatment options. The company has successfully developed several promising drug candidates and is actively engaged in clinical trials to bring these therapies to market. With its commitment to improving patient outcomes, Oncology Pharma Inc continues to strive towards advancing cancer care through groundbreaking research and development initiatives.

Who are the main competitors of Oncology Pharma in the market?

The main competitors of Oncology Pharma Inc in the market include other pharmaceutical companies specializing in oncology treatments, such as Pfizer Inc., Merck & Co. Inc., and Novartis International AG. These established companies also operate in the same space, developing and providing innovative cancer therapies and drugs. Competitors often vary based on specific subsegments within the oncology market, including targeted therapies, immunotherapies, and chemotherapy drugs. While Oncology Pharma Inc aims to differentiate its offerings through unique drug candidates and therapeutic approaches, it faces a competitive landscape where these key players continue to drive advancements in cancer treatment options.

In which industries is Oncology Pharma primarily active?

Oncology Pharma Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Oncology Pharma?

The business model of Oncology Pharma Inc revolves around developing and commercializing innovative therapies for the treatment of various forms of cancer. Oncology Pharma Inc focuses on identifying novel drug candidates that have the potential to address unmet medical needs in cancer care. By conducting extensive research and clinical trials, the company aims to bring new and effective treatments to patients, with a particular emphasis on personalized and targeted therapies. Oncology Pharma Inc's business model emphasizes collaboration with strategic partners, including healthcare providers and pharmaceutical companies, to accelerate the development and delivery of life-saving cancer treatments.

What is the P/E ratio of Oncology Pharma 2024?

The P/E ratio cannot be calculated for Oncology Pharma at the moment.

What is the P/S ratio of Oncology Pharma 2024?

The P/S cannot be calculated for Oncology Pharma currently.

What is the AlleAktien quality score of Oncology Pharma?

The AlleAktien quality score for Oncology Pharma is 3/10.

What is the revenue of Oncology Pharma 2024?

The revenue cannot currently be calculated for Oncology Pharma.

How high is the profit of Oncology Pharma 2024?

The profit cannot currently be calculated for Oncology Pharma.

What is the business model of Oncology Pharma

Oncology Pharma Inc is a biopharmaceutical company focused on the development and marketing of medications for the treatment of cancer. The company's business model includes various divisions, including research and development, as well as sales and marketing. The research and development department of Oncology Pharma Inc focuses on the identification and development of drugs that target specific types of tumors and can effectively combat them. The company utilizes cutting-edge technologies and methods to research new cancer medications based on innovative approaches. These approaches aim to identify and exploit the weaknesses of cancer cells in order to inhibit their growth and spread. Oncology Pharma Inc already has several drug candidates that are currently in the clinical development phase. These medications are able to combat a broad range of cancer diseases, including those that are difficult to treat. The company also collaborates closely with universities, research organizations, and other biopharmaceutical companies to gain new insights into cancer therapy and develop innovative treatment methods. The sales and marketing department of Oncology Pharma Inc ensures that the company's medications are effectively marketed and that patients, doctors, and other healthcare professionals are informed about their effectiveness and benefits. The company also works closely with healthcare organizations and government agencies to ensure that its products meet the highest standards of quality and safety. Oncology Pharma Inc's products also include a wide range of state-of-the-art cancer diagnostics. These diagnostics enable doctors to more accurately determine the type and progression of cancer development in their patients and recommend tailored treatments. The company also develops specialized medications to support immunotherapy, which helps patients' immune systems in fighting cancer cells. The business model of Oncology Pharma Inc is based on a strong research and development department that develops innovative drug candidates, as well as an effective sales and marketing department that successfully brings them to the market. The company offers a wide range of cancer medications and diagnostics that have been developed on a solid scientific foundation and provide genuine clinical benefit. With its commitment to research, innovation, and safety, Oncology Pharma Inc is well positioned to become a leading company in cancer therapy and make a significant contribution to improving the health of patients worldwide.

What is the Oncology Pharma dividend?

Oncology Pharma pays a dividend of 0 USD distributed over payouts per year.

How often does Oncology Pharma pay dividends?

The dividend cannot currently be calculated for Oncology Pharma or the company does not pay out a dividend.

What is the Oncology Pharma ISIN?

The ISIN of Oncology Pharma is US68235J2015.

What is the Oncology Pharma WKN?

The WKN of Oncology Pharma is A2QEWD.

What is the Oncology Pharma ticker?

The ticker of Oncology Pharma is ONPH.

How much dividend does Oncology Pharma pay?

Over the past 12 months, Oncology Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncology Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Oncology Pharma?

The current dividend yield of Oncology Pharma is .

When does Oncology Pharma pay dividends?

Oncology Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncology Pharma?

Oncology Pharma paid dividends every year for the past 0 years.

What is the dividend of Oncology Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncology Pharma located?

Oncology Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncology Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncology Pharma from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Oncology Pharma pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Oncology Pharma in the year 2023?

In the year 2023, Oncology Pharma distributed 0 USD as dividends.

In which currency does Oncology Pharma pay out the dividend?

The dividends of Oncology Pharma are distributed in USD.

All fundamentals about Oncology Pharma

Our stock analysis for Oncology Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncology Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.